INSTITUTIONAL BIOSAFETY COMMITTEE REVIEW

MEETING MINUTES

Meeting Date:	**Monday, December 29, 2025**
Time:	10:00 am Eastern Time
Location:	Zoom Teleconference
Institution:	Hackensack Meridian Health, Hackensack, NJ
Principal Investigator:	**David S. Siegel, MD, PhD**
Protocol:	Poseida Therapeutics, Inc., **P-BCMA-ALLO1-001**
NCT Number:	NCT04960579
Meeting Type:	Continuing Review of Protocol and Site
Title:	Open-Label, Multicenter, Phase 1 Study to Assess the Safety of P-BCMA-ALLO1 in Subjects with Relapsed / Refractory Multiple Myeloma (MM)

1. Call to order:

The Meeting was called to order at 10:08 am Eastern Time.

2. Introductions and orientation:

Introductions were made and the Chair oriented members to the meeting procedures.

3. Declaration of quorum:

Six voting members were present, including two local members unaffiliated with the institution and the Institution's Biosafety Officer. Also present was IBC Services staff. The Chair declared that a quorum was present.

4. Conflict of Interest:

The Chair requested that voting members report any conflict of interest regarding this meeting. No conflicts of interest were reported.

5. Public posting:

The Biosafety Officer confirmed that notice of the meeting was publicly posted. No public comments were received by the site or the Committee regarding this review.

6. Approval of previous meeting minutes:

Minutes Approved - YES: 6 NO: 0 ABSTAIN: 0

7. Review of proposed research:

The Chair provided an overview of the protocol and status of the study.

The Chair noted changes since the last review.

Point of Discussion:

1. The Committee discussed the Continuing Review Report Form and noted that the study has not been activated at the site and therefore there were no deviations, research-related incidents, or changes at the site since the last IBC review.

8. Determination for biosafety level and period of IBC oversight:

The Committee previously determined that **BSL-2 containment facilities and practices** are required for P-BCMA-ALLO1, since it consists of primary human cells modified using a plasmid and mRNA. The Committee reaffirmed this determination.

The Committee previously determined that IBC oversight will continue for **3 months after the last subject's last dose of PBCMA-ALLO1 locally**, provided all other criteria for study closure are met. The Committee reaffirmed this determination.

9. Vote on the Protocol:

The Committee voted for the following determination on the Protocol:

X	APPROVED
	CONDITIONALLY APPROVED
	TABLED
	DISAPPROVED

DETERMINATION VOTE - YES: 6 NO: 0 ABSTAIN: 0

10. Review of proposed facilities and practices:

The Chair provided an overview of the arrangement for the facilities and practices.

Points of Discussion:

1. The Committee noted that the primary study contact listed on page 1 of the Site Inspection Checklist does not match the primary study contact listed on page 10. The Committee recommended that the Site Inspection Checklist be revised to list the correct primary study contact in both sections.
2. The Committee determined that it was appropriate to include Sections 2.2.2 and 2.2.3 in the Biosafety Guidelines Addendum for Allogeneic Cells, as one covers removing a set volume from the infusion bag for subsequent dosing via gravity flow IV infusion and the other covers withdrawing a set volume into a syringe for subsequent dosing via IV push infusion.

11. Site requirements:

The Chair reviewed training and communication requirements for maintaining IBC approval with the Biosafety Officer.

12. Vote on the Site:

The Committee voted for the following determination on the Site:

X	APPROVED
	CONDITIONALLY APPROVED
	TABLED
	DISAPPROVED

DETERMINATION VOTE - YES: 6 NO: 0 ABSTAIN: 0

13. Advice to the Institution: None.

14. Meeting adjourned: The meeting was adjourned at 10:18 am Eastern Time.